Dynavax Technologies Corporation
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company founded in 1996 and headquartered in Emeryville, California, develops and commercializes innovative vaccines leveraging Toll-like Receptor agonist technology, including its proprietary CpG 1018 adjuvant; HEPLISAV-B, a two-dose adjuvanted hepatitis B vaccine approved in the United States, European Union and Great Britain for adults aged 18 years and older to prevent infection from all known subtypes of the hepatitis B virus; and CpG 1018 adjuvant, supplied to partners for use in multiple COVID-19 vaccines. The company advances a pipeline of novel vaccine candidates addressing infectious diseases and biodefense needs, such as an adjuvanted plague (rF1V) vaccine fully funded by the U.S. Department of Defense, with a Phase 2 trial initiation planned for the third quarter of 2025 under a $30 million agreement executed in late 2024; and investigational vaccines for shingles prevention and other indications. Dynavax conducts operations primarily in the United States and Europe, with manufacturing in Düsseldorf, Germany, targeting hospitals, clinics, government agencies, integrated delivery networks and wholesalers. In November 2025, Dynavax entered an exclusive worldwide license agreement with Vaxart, Inc., for an oral COVID-19 vaccine candidate, providing a $25 million upfront payment and $5 million equity investment, with Vaxart funding the ongoing Phase 2b trial through an FDA End-of-Phase 2 meeting and topline data expected in late 2026. The company also announced a new $100 million share repurchase program alongside its third quarter 2025 financial results, reporting total revenues of $94.9 million, an 18% increase year-over-year, and continues strategic business development to expand its commercial infrastructure.
Blair William & Co. IL Sells 51,038 Shares of Dynavax Technologies Corporation $DVAX
35,615 Shares in Dynavax Technologies Corporation $DVAX Acquired by AXQ Capital LP
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
AlphaQuest LLC Boosts Stock Position in Dynavax Technologies Corporation $DVAX
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
Dynavax Technologies Corporation (NASDAQ:DVAX) Receives Average Rating of “Hold” from Brokerages
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF
Dynavax Technologies Corporation $DVAX Shares Sold by Chicago Capital LLC
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Halper Sadeh LLC Encourages DVAX, CWAN, DBRG Shareholders to Contact the Firm to Discuss Their Rights
CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Dynavax Technologies (NASDAQ:DVAX) COO David Novack Sells 30,000 Shares
Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX
Shareholder Alert: The Ademi Firm investigates whether DigitalBridge Group, Inc. is obtaining a Fair Price for its Public Shareholders
Exchange Traded Concepts LLC Has $2 Million Stake in Dynavax Technologies Corporation $DVAX
Nvidia, Sobr Safe And 3 Stocks To Watch Heading Into Friday
Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here's Why
Why Dynavax Stock Soared Today
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio